Suppr超能文献

巴塞罗那临床肝癌系统的列线图用于肝癌个体预后预测。

Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma.

机构信息

Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.

出版信息

Liver Int. 2016 Oct;36(10):1498-506. doi: 10.1111/liv.13114. Epub 2016 Apr 4.

Abstract

BACKGROUND & AIMS: The predictive accuracy of the Barcelona Clinic Liver Cancer (BCLC) staging system on a single patient is not clear. This study aimed to develop a nomogram to predict individualized survival of patients with hepatocellular carcinoma (HCC) based on the BCLC system.

METHODS

A total of 3179 patients were randomly grouped into derivation (n = 2119) and validation (n = 1060) sets. The multivariate Cox proportional hazards model was used to generate the nomogram from tumour burden, cirrhosis and performance status (PS). The performance of the nomogram was evaluated by concordance indices and calibration tests.

RESULTS

Beta coefficients from the Cox model were used to assign nomogram points to different degrees of tumour burden, Child-Turcotte-Pugh classification and PS. A nomogram with a scale of 0-26 was developed and the predicted survival rates at 3 and 5 years were calculated. The derivation set had a concordance index of 0.766 (95% confidence interval [CI]: 0.686-0.838); and the validation set showed a concordance index of 0.775 (95% CI: 0.607-0.909). The calibration plots were close to the 45-degree line for 3- and 5-year survival prediction of BCLC stages 0-C patients in both derivation and validation groups. For BCLC stage D patients, calibration plots in both groups showed deviation from the 45-degree line for 3- and 5-year prediction.

CONCLUSIONS

This study provides quantitative evidence to support the prognostic ability of BCLC system. This straightforward and easy-to-use nomogram may accurately predict the survival at 3 and 5 years for individual HCC patient except for BCLC stage D patients.

摘要

背景与目的

巴塞罗那临床肝癌(BCLC)分期系统对单个患者的预测准确性尚不清楚。本研究旨在开发一种列线图,根据 BCLC 系统预测肝细胞癌(HCC)患者的个体化生存。

方法

共纳入 3179 例患者,随机分为推导组(n = 2119)和验证组(n = 1060)。采用多变量 Cox 比例风险模型,根据肿瘤负荷、肝硬化和体能状态(PS)生成列线图。通过一致性指数和校准检验评估列线图的性能。

结果

Cox 模型的β系数用于为不同程度的肿瘤负荷、Child-Turcotte-Pugh 分级和 PS 分配列线图点。建立了一个 0-26 分的列线图,并计算了 3 年和 5 年的预测生存率。推导组的一致性指数为 0.766(95%置信区间[CI]:0.686-0.838);验证组的一致性指数为 0.775(95%CI:0.607-0.909)。校准图在推导组和验证组中,BCLC 0-C 期患者的 3 年和 5 年生存率预测均接近 45 度线。对于 BCLC 期 D 患者,两组的校准图在 3 年和 5 年预测中均偏离 45 度线。

结论

本研究提供了定量证据支持 BCLC 系统的预后能力。除了 BCLC 期 D 患者外,这种简单易用的列线图可以准确预测 HCC 患者的 3 年和 5 年生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验